Abstract RT can not only give the tumor a high dose of irradiation,but also protect the surrounding normal tissue as much as possible. SBRT is consistent with the general law of the dose-effect of tumor radiation biology,which the high dose radiation will increase the damage to the tumor. Compared to conventional radiation therapy,SBRT has less fractions (1-5),and higher single dose (8-30 Gy).The LQ (Linear-Quadratic) model which applied in the multi-fractions conventional radiation therapy may not evaluate the biological effect accurately in large dose radiation. Some scholars proposed USC (universal survival curve),LQL (linear-quadratic-linear),gLQ (generalized-linear-quadratic) modified models to intent to predict the radiobiology better in SBRT.SBRT has become one of the important methods to treat the tumor in Lung,Live,Spine and other organs. Advances in radiation biology can further explore the clinical application of SBRT,which contributes to improve the therapeutic effect of tumor radiotherapy
Corresponding Authors:
Fu Jie,Email:littlestrong15@sjtu.edu.cn
Cite this article:
Yi Peiqiang,Fu Jie. Advances of radiobiology in stereotactic body radiation therapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(12): 1379-1383.
Yi Peiqiang,Fu Jie. Advances of radiobiology in stereotactic body radiation therapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(12): 1379-1383.
[1] Timmerman RD,Kavanagh BD,Cho LC,et al. Stereotactic body radiation therapy in multiple organ sites[J].J Clin Oncol,2007,25(8):947-952. [2] Garcia-Barros M,Paris F,Cordon-Cardo C,et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis[J].Science,2003,300(5622):1155-1159. [3] Park HJ,Griffin RJ,Hui S,et al. Radiation-induced vascular damage in tumors:implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)[J].Radiat Res,2012,177(3):311-327. [4] Lee Y,Auh SL,Wang Y,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:changing strategies for cancer treatment[J].Blood,2009,114(3):589-595.10.1182/blood-2009-02-206870. [5] Postow MA,Callahan MK,Barker CA,et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J].N Engl J Med,2012,366(10):925-931. [6] Hiniker SM,Chen DS,Reddy S,et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy[J].Transl Oncol,2012,5(6):404-407. [7] Nobler MP.The abscopal effect in malignant lymphoma and its relationship to lymphocyte circulation[J].Radiology,1969,93(2):410-412. [8] Ehlers G,Fridman M.Abscopal effect of radiation in papillary adenocarcinoma[J].Br J Radiol,1973,46(543):220-222. [9] Takaya M,Niibe Y,Tsunoda S,et al. Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma—a case report[J].Anticancer Res,2007,27(1b):499-503. [10] Okuma K,Yamashita H,Niibe Y,et al. Abscopal effect of radiation on lung metastases of hepatocellular carcinoma:a case report[J].J Med Case Rep,2011,5:111.10.1186/1752-1947-5-111. [11] Ohba K,Omagari K,Nakamura T,et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis[J].Gut,1998,43(4):575-577. [12] Twyman-Saint Victor C,Rech AJ,Maity A,et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J].Nature,2015,520(7547):373-377. [13] Park C,Papiez L,Zhang S,et al. Universal survival curve and single fraction equivalent dose:useful tools in understanding potency of ablative radiotherapy[J].Int J Radiat Oncol Biol Phys,2008,70(3):847-852. [14] Guerrero M,Carlone M.Mechanistic formulation of a lineal-quadratic-linear (LQL) model:split-dose experiments and exponentially decaying sources[J].Med Phys,2010,37(8):4173-4181. [15] Wang JZ,Huang Z,Lo SS,et al. A generalized linear-quadratic model for radiosurgery,stereotactic body radiation therapy,and high-dose rate brachytherapy[J].Sci Transl Med,2010,2(39):39ra48. [16] Wennberg B,Lax I.The impact of fractionation in SBRT:analysis with the linear quadratic model and the universal survival curve model[J].Acta Oncol,2013,52(5):902-909.10.3109/0284186X.2012.728292. [17] Guckenberger M,Klement RJ,Allgauer M,et al. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer[J].Radiother Oncol,2013,109(1):13-20.10.1016/j.radonc.2013.09.005. [18] Santiago A,Barczyk S,Jelen U,et al. Challenges in radiobiological modeling:can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?[J].Radiat Oncol,2016,11:67.10.1186/s13014-016-0643-5. [19] Ohri N,Dicker AP,Lawrence YR.Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data[J].Int J Radiat Oncol Biol Phys,2012,83(1):385-393.10.1016/j.ijrobp.2011.06.1990. [20] Nagata Y,Hiraoka M,Shibata T,et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer:Japan Clinical Oncology Group Study JCOG0403[J].Int J Radiat Oncol Biol Phys,2015,93(5):989-996.10.1016/j.ijrobp.2015.07.2278. [21] Videtic GM,Hu C,Singh AK,et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage Ⅰ peripheral non-small cell lung cancer:NRG Oncology RTOG 0915(NCCTG N0927)[J].Int J Radiat Oncol Biol Phys,2015,93(4):757-764.10.1016/j.ijrobp.2015.07.2260. [22] Timmerman RD,Hu C,Michalski J,et al. Long-term results of RTOG 0236:a phase Ⅱ trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage i non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2014,90(1):1675-1678.查不到 [23] Fowler JF.Sensitivity analysis of parameters in linear-quadratic radiobiologic modeling[J].Int J Radiat Oncol Biol Phys,2009,73(5):1532-1537.10.1016/j.ijrobp.2008.11.039. [24] Onishi H,Araki T,Shirato H,et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ nonsmall cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multiinstitutional study[J].Cancer,2004,101(7):1623-1631. [25] Guckenberger M,Wulf J,Mueller G,et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors:relevance of 4D dose calculation[J].Int J Radiat Oncol Biol Phys,2009,74(1):47-54.10.1016/j.ijrobp.2008.06.1939. [26] Rusthoven KE,Kavanagh BD,Burri SH,et al. Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for lung metastases[J].J Clin Oncol,2009,27(10):1579-1584.10.1200/JCO.2008.19.6386. [27] Takeda A,Sanuki N,Tsurugai Y,et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation[J].Cancer,2016,122(13):2041-2049.10.1002/cncr.30008. [28] Kim JW,Seong J,Lee IJ,et al. Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma[J].Oncotarget,2016,7(26):40756-40766. 10.18632/oncotarget.9450. [29] Bujold A,Massey CA,Kim JJ,et al. Sequential phase I and Ⅱ trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J].J Clin Oncol,2013,31(13):1631-1639.10.1200/JCO.2012.44.1659. [30] Scorsetti M,Comito T,Cozzi L,et al. The challenge of inoperable hepatocellular carcinoma (HCC):results of a single-institutional experience on stereotactic body radiation therapy (SBRT)[J].J Cancer Res Clin Oncol,2015,141(7):1301-1309.10.1007/s00432-015-1929-y. [31] Sanuki N,Takeda A,Oku Y,et al. Stereotactic body radiotherapy for small hepatocellular carcinoma:a retrospective outcome analysis in 185 patients[J].Acta Oncol,2014,53(3):399-404.10.3109/0284186X.2013.820342. [32] Jang WI,Kim MS,Bae SH,et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma[J].Radiat Oncol,2013,8:250.10.1186/1748-717X-8-250. [33] Huertas A,Baumann AS,Saunier-Kubs F,et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma[J].Radiother Oncol,2015,115(2):211-216.10.1016/j.radonc.2015.04.006. [34] Wahl DR,Stenmark MH,Tao Y,et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma[J].J Clin Oncol,2016,34(5):452-459.10.1200/JCO.2015.61.4925. [35] Andolino DL,Johnson CS,Maluccio M,et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2011,81(4):e447-453.10.1016/j.ijrobp.2011.04.011. [36] Tse RV,Hawkins M,Lockwood G,et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J].J Clin Oncol,2008,26(4):657-664.10.1200/JCO.2007.14.3529. [37] Andratschke NH,Nieder C,Heppt F,et al. Stereotactic radiation therapy for liver metastases:factors affecting local control and survival[J].Radiat Oncol,2015,10:69.10.1186/s13014-015-0369-9. [38] Andratschke N,Parys A,Stadtfeld S,et al. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases[J].Radiat Oncol,2016,11:74.10.1186/s13014-015-0369-9. [39] Tozzi A,Comito T,Alongi F,et al. SBRT in unresectable advanced pancreatic cancer:preliminary results of a mono-institutional experience[J].Radiat Oncol,2013,8:148.10.1186/1748-717X-8-148. [40] Gurka MK,Collins SP,Slack R,et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer:a pilot trial demonstrating safety[J].Radiat Oncol,2013,8:44.10.1186/1748-717X-8-44. [41] Rajagopalan MS,Heron DE,Wegner RE,et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer[J].Radiat Oncol,2013,8:254.10.1186/1748-717X-8-254. [42] Comito T,Cozzi L,Clerici E,et al. Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study[J].Technol Cancer Res Treat,2016.10.1177/1533034616650778. [43] Hoyer M,Roed H,Sengelov L,et al. Phase-Ⅱ study on stereotactic radiotherapy of locally advanced pancreatic carcinoma[J].Radiother Oncol,2005,76(1):48-53. [44] Koong AC,Christofferson E,Le QT,et al. Phase Ⅱ study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer[J].Int J Radiat Oncol Biol Phys,2005,63(2):320-323. [45] Nakamura A,Shibuya K,Matsuo Y,et al. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2012,84(2):369-375.10.1016/j.ijrobp.2011.12.026. [46] Huang J,Robertson JM,Ye H,et al. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma[J].Int J Radiat Oncol Biol Phys,2012,83(4):1120-1125.10.1016/j.ijrobp.2011.09.022. [47] Pollom EL,Alagappan M,von Eyben R,et al. Single-versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma:outcomes and toxicity[J].Int J Radiat Oncol Biol Phys,2014,90(4):918-925.10.1016/j.ijrobp.2014.06.066. [48] Garg AK,Shiu AS,Yang J,et al. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases[J].Cancer,2012,118(20):5069-5077.10.1002/cncr.27530. [49] Ryu S,Pugh SL,Gerszten PC,et al. RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases:phase 2 results[J].Pract Radiat Oncol,2014,4(2):76-81.10.1016/j.prro.2013.05.001. [50] Chang EL,Shiu AS,Mendel E,et al. Phase Ⅰ/Ⅱ study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure[J].J Neurosurg Spine,2007,7(2):151-160.10.3171/SPI-07/08/151 [51] Gerszten PC,Burton SA,Welch WC,et al. Single-fraction radiosurgery for the treatment of spinal breast metastases[J].Cancer,2005,104(10):2244-2254. [52] Amdur RJ,Bennett J,Olivier K,et al. A prospective,phase Ⅱ study demonstrating the potential value and limitation of radiosurgery for spine metastases[J].Am J Clin Oncol,2009,32(5):515-520.10.1097/COC.0b013e318194f70f. [53] Cunha MV,Al-Omair A,Atenafu EG,et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT):analysis of predictive factors[J].Int J Radiat Oncol Biol Phys,2012,84(3):e343-349.10.1016/j.ijrobp.2012.04.034. [54] Boehling NS,Grosshans DR,Allen PK,et al. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases[J].J Neurosurg Spine,2012,16(4):379-386.10.3171/2011.11.SPINE116.
2016, Vol. 25 
